



**Fabian Meienberg**

**Contact**

Fabian Meienberg

## Publications (4)

Bilz S, Flückiger M, Meienberg F, Falconnier C, Keller U, Puder J. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial. *PLoS one* 2018; 13:e0202007.

Hornemann T, Baumgartner M, Christ E, Bilz S, Meienberg F, Jung H, Gautschi M, Cremonesi A, Zhakupova A, Hagenbuch N, Alecu I, Hochuli M. Disturbed sphingolipid metabolism with elevated 1-deoxysphingolipids in glycogen storage disease type I - A link to metabolic control. *Mol Genet Metab* 2018; 125:73-78.

Navarini A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker L, Heijnen I, Daikeler T, Gebbers J, Grimbacher B, Sansom D, Jeker R, Hess C, Jauch A, Kistner A, Bigler M, Hruz P, Berger C, Hou T, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg S, Kämpe O, Burgener A, Marquardsen F, Baldin F, Recher M. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. *J Allergy Clin Immunol* 2016; 139:1043-1046.e5.

Seelig E, Bilz S, Keller U, Meienberg F, Christ-Crain M. Concentrations of the stress hormone copeptin increase upon hypoglycaemia in patients with type 1 diabetes dependent of hypoglycaemia awareness. *PLoS one* 2013; 8:e72876.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)